Stealthy Silverback recruits Seattle Genetics’ Eric Dobmeier as CEO, filling C-suite with oncology talent
A stealthy Silverback Therapeutics has been building up its C-suite with top talent from a pair of high profile biotechs in the Seattle area.
GeekWire reported over the weekend that Silverback recruited Seattle Genetics $SGEN COO Eric Dobmeier to take the helm at Silverback. Seattle Genetics reported Dobmeier’s planned departure in an SEC filing on Friday.
Orbimed’s Peter Thompson came in with a $10 million ante to a $60 million launch round last year, paving the way to recruiting Seattle Genetics’ VP of manufacturing Mike Sun. And the tech wire service added that Juno contributed Sam Blackman, a senior medical director at the I/O company, as head of clinical development while Valerie Odegard stepped over to become SVP of research.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.